您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Ampalex
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Ampalex
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Ampalex图片
CAS NO:154235-83-3
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
100mg电议

产品介绍
Ampalex (BDP 12) 是一种安帕金，可作为 AMPA 受体阳性变构调节剂，用于阿尔茨海默病、精神分裂症和轻度认知障碍 (MCI) 的研究。
Cas No.154235-83-3
别名安帕来斯; BDP 12
化学名piperidin-1-yl(quinoxalin-6-yl)methanone
Canonical SMILESC1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2
分子式C14H15N3O
分子量241.29
溶解度≥ 13.45 mg/mL in DMSO, ≥ 92 mg/mL in EtOH, ≥ 24.1 mg/mL in Water with gentle warming
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). IC50 value: Target: AMPA receptorAmpalex ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Researches suggest that AMPA receptors may be potential pharmaceutical targets for the treatment of neurodegenerative diseases, and highlights AMPAkines, in particular, as possible therapeutic agents.

References:
[1]. Broberg BV, Glenth j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009
[2]. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61.
[3]. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465-72.
[4]. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20.
[5]. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.